Michael Benkowitz Net Worth

The estimated Net Worth of Michael Benkowitz is at least $15.3 Milhão dollars as of 7 August 2024. Mr. Benkowitz owns over 25,000 units of United Therapeutics Corp stock worth over $6,923,800 and over the last 8 years he sold UTHR stock worth over $0. In addition, he makes $8,383,190 as President e Chief Operating Officer at United Therapeutics Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Benkowitz UTHR stock SEC Form 4 insiders trading

Michael has made over 39 trades of the United Therapeutics Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of UTHR stock worth $2,960,250 on 7 August 2024.

The largest trade he's ever made was exercising 32,200 units of United Therapeutics Corp stock on 6 May 2024 worth over $5,258,260. On average, Michael trades about 5,078 units every 28 days since 2016. As of 7 August 2024 he still owns at least 20,000 units of United Therapeutics Corp stock.

You can see the complete history of Mr. Benkowitz stock trades at the bottom of the page.

Michael Benkowitz biography

Michael Benkowitz serves as President, Chief Operating Officer of the Company. He joined United Therapeutics in 2011 as Executive Vice President, Organizational Development. In this role, he was responsible for most companywide administrative functions, including human resources, information technology, corporate real estate and risk management, and was also responsible for many of our business development efforts and oversight of several of company key collaborations. He was promoted to President and Chief Operating Officer in June 2016, when he also became responsible for all of company commercial and medical affairs activities.

What is the salary of Michael Benkowitz?

As the President e Chief Operating Officer of United Therapeutics Corp, the total compensation of Michael Benkowitz at United Therapeutics Corp is $8,383,190. There are 1 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.

How old is Michael Benkowitz?

Michael Benkowitz is 48, he's been the President e Chief Operating Officer of United Therapeutics Corp since 2016. There are 20 older and no younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.

What's Michael Benkowitz's mailing address?

Michael's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.

Insiders trading at United Therapeutics Corp

Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli, eRoger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.

What does United Therapeutics Corp do?

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Complete history of Mr. Benkowitz stock trades at United Therapeutics Corp

United Therapeutics Corp executives and stock owners

United Therapeutics Corp executives and other stock owners filed with the SEC include:

• Martine Rothblatt,
  Chairman of the Board, Chief Executive Officer
• Michael Benkowitz,
  President, Chief Operating Officer
• Paul Mahon,
  Executive Vice President, General Counsel, Corporate Secretary
• James Edgemond,
  Chief Financial Officer, Treasurer
• Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
  Founder, Chairman & CEO
• Dr. Martine A. Rothblatt,
  Founder, Chairman & CEO
• Michael I. Benkowitz,
  Pres & COO
• Paul A. Mahon,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Paul A. Mahon J.D.,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James C. Edgemond,
  CFO & Treasurer
• Christopher Patusky,
  Lead Independent Vice Chairman of the Board
• Christopher Causey,
  Independent Director
• Richard Giltner,
  Independent Director
• Louis Sullivan,
  Independent Director
• Tommy Thompson,
  Independent Director
• Nilda Mesa,
  Independent Director
• Judy Olian,
  Independent Director
• Katherine Klein,
  Independent Director
• Raymond Kurzweil,
  Independent Director
• Raymond Dwek,
  Independent Director
• Linda Maxwell,
  Director
• Dewey Steadman C.F.A.,
  Head of Investor Relations
• Leigh Peterson,
  VP of Product Devel.
• Gil Golden,
  Sr. VP & Chief Medical Officer
• Patrick Poisson,
  Exec. VP of Technical Operations
• Kevin T. Gray,
  Sr. VP of Strategic Operations & Logistics
• Holly Hobson,
  Associate VP of HR
• Dewey Steadman C.F.A., CFA,
  Head of Investor Relations
• Jan Malcolm,
  
• Ray Kurzweil,
  
• Roger Jeffs,
  President & COO
• Fred T Hadeed,
  EVP & CFO
• David Zaccardelli,
  EVP & Chief Operating Officer
• John Maxim Ferrari,
  CFO & Treasurer
• R Paul Gray,
  Director
• Lilly & Co Eli,
  Director, Chairman and CEO